Cargando…
Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
Non-response to intravitreal ranibizumab represents a frequent problem in pachychoroid neovasculopathy (PNV). To investigate the effectivity of switching to aflibercept, the database of the Ludwig Maximilians University, Munich, was screened for patients fulfilling the following inclusion criteria:...
Autores principales: | Schworm, Benedikt, Luft, Nikolaus, Keidel, Leonie F., Herold, Tina R., Wolf, Armin, Priglinger, Siegfried G., Siedlecki, Jakob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242401/ https://www.ncbi.nlm.nih.gov/pubmed/32439930 http://dx.doi.org/10.1038/s41598-020-65370-w |
Ejemplares similares
-
Scleral Thickness as a Risk Factor for Central Serous Chorioretinopathy and Pachychoroid Neovasculopathy
por: Keidel, Leonie F., et al.
Publicado: (2023) -
Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy
por: Schworm, Benedikt, et al.
Publicado: (2021) -
Pachychoroid Neovasculopathy Disguising as Age-Related Macular Degeneration Treated by Spironolactone and Anti-VEGF Combination Therapy
por: Keidel, Leonie F., et al.
Publicado: (2021) -
Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy
por: Siedlecki, Jakob, et al.
Publicado: (2023) -
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)